In vitro studies have shown that ERBB2 mutations are associated with resistance to endocrine therapy, indeed in a HER2 mutant breast cancer cell model, authors found that HER2-mutated cells were resistant to estrogen deprivation, similarly to ESR1 mutation, and sensitive to fulvestran plus neratinib [51]. This evidence concerns the gene ERBB2 and breast carcinoma.